Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290006 | 0.79 | POLB (0.63) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL7945941 | 0.79 | POLB (0.58) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL6292873 | 0.77 | POLB (0.53) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL30730119 | 0.74 | CA12 (0.38) | POLBCA12CA1CA2CA7 | |
| SCHEMBL7003913 | 0.73 | POLB (0.56) | POLBRAB9ANPC1SMN1; SMN2CA12 | |
| SCHEMBL9246548 | 0.70 | POLB (0.60) | POLBTNFSF11TSHRBACE1KDM4E | |
| SCHEMBL167840 | 0.69 | POLB (0.38) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL28602356 | 0.69 | CYP3A4 (0.61) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL11525740 | 0.69 | POLB (1.00) | POLBTNFSF11RAB9ANPC1PKM | |
| SCHEMBL17185142 | 0.68 | CYP4F2 (0.39) | POLBTNFSF11RAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0915832-B1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX INC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-5877297-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872224-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | POLB 1127/4885TNFSF11 3866/4885RAB9A 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.